Advertisement

Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies

  • Myrto Boukovala
  • Nicholas Spetsieris
  • Eleni EfstathiouEmail author
Review Article

Abstract

Prostate cancer commonly affects older men, with one out of five patients being diagnosed at 75 years or older. Elderly patients are more likely to have reduced performance and nutritional status, increased comorbidities, polypharmacy, and altered host-dependent pharmacokinetics and pharmacodynamics. Moreover, elderly patients are often underrepresented in clinical trials, mainly because of comorbidities and decline in performance status. The International Society of Geriatric Oncology recommends management of elderly patients according to fitness and personal preference, rather than chronological age. Since androgen signaling has a nodal role in prostate cancer progression, androgen-targeting agents remain the mainstay of systemic therapy for this disease. However, the potential benefit of these treatments may be compromised by toxicity, especially in elderly patients. Hence, management decisions require evidence-based consideration of both potential benefits and risks on an individualized basis. Furthermore, especially elderly patients should undergo geriatric screening and must be actively monitored during treatment to detect adverse events early and prevent complications. A personalized and vigilant approach could provide the elderly patient with the optimal benefits of existing and emerging prostate cancer treatments, while sparing them the risks of excessive toxicity and avoiding overtreatment.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

MB and NS declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. EE has received research grants from Janssen, Sanofi and Astellas, honoraria from Sanofi, Bayer, Astellas, Tolmar, and Janssen, and payment for lectures from Janssen.

References

  1. 1.
    National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: prostate cancer. [cited 11/20/2018].Google Scholar
  2. 2.
    World Health Organization. International Agency for Research on Cancer—GLOBOCAN 2018. [cited 11/20/2018].Google Scholar
  3. 3.
    United States Census Bureau. Projections of the populations of the United States: 1982 to 2050 (advance report). 1982 [cited 11/20/2018].Google Scholar
  4. 4.
    Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Kongsted P, Svane IM, Lindberg H, Sengelov L. Predictors of chemotherapy-induced toxicity and treatment outcomes in elderly versus younger patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2016;14(6):e559–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, et al. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194(5):1277–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014;25(2):429–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, et al. Radiotherapy for elderly patients aged >/=75 years with clinically localized prostate cancer-is there a role of brachytherapy? J Clin Med. 2018;7(11):424.Google Scholar
  9. 9.
    Lockett J, Sauma S, Radziszewska B, Bernard MA. Adequacy of inclusion of older adults in NIH-funded phase III clinical trials. J Am Geriatr Soc. 2019;67(2):218–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet. 2003;42(14):1213–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet. 1986;11(3):223–35.Google Scholar
  12. 12.
    Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010;73(1):68–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–14.CrossRefPubMedGoogle Scholar
  14. 14.
    Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. 2017;72(4):521–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CG, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85(19):1571–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol. 2017;27(5):415–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Moller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer. 2015;136(8):1940–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostat Dis. 2017;20(2):146–55.CrossRefGoogle Scholar
  19. 19.
    Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162(2):454.CrossRefPubMedGoogle Scholar
  20. 20.
    Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, et al. DNA repair in prostate cancer: biology and clinical implications. Eur Urol. 2017;71(3):417–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.Google Scholar
  22. 22.
    Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017.  https://doi.org/10.1200/PO.17.00029.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Abidi SH, Bilwani F, Ghias K, Abbas F. Viral etiology of prostate cancer: genetic alterations and immune response. A literature review. Int J Surg. 2018;52:136–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol. 1992;147(3 Pt 2):798–803.CrossRefPubMedGoogle Scholar
  25. 25.
    Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991;67(12):3057–64.Google Scholar
  26. 26.
    Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 1994;144(4):735–46.Google Scholar
  27. 27.
    Nuclear Receptors Nomenclature C. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97(2):161-3.Google Scholar
  28. 28.
    Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33(2–3):413–27.CrossRefPubMedGoogle Scholar
  29. 29.
    National Comprehensive Cancer network (NCCN) clinical practice guidelines in oncology—prostate cancer. Version 4.2018 [cited 11/20/2018].Google Scholar
  30. 30.
    Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer. 2015;51(10):1283–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.CrossRefPubMedGoogle Scholar
  33. 33.
    Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017;8(2):3724–45.CrossRefPubMedGoogle Scholar
  36. 36.
    Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, Hu JC, et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur Urol. 2015;68(1):32–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, et al. Low-risk prostate cancer: identification, management, and outcomes. Eur Urol. 2017;72(2):238–49.CrossRefPubMedGoogle Scholar
  38. 38.
    Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA. 2015;314(1):80–2.CrossRefPubMedGoogle Scholar
  39. 39.
    Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–11.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143–50.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. J Clin Oncol. 2015;33(19):2151–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Fossa SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684–91.CrossRefPubMedGoogle Scholar
  43. 43.
    Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol. 2015;33(7):716–22.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012;62(2):213–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Konety BR, Cowan JE, Carroll PR, Ca PI. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179(5):1797–803 (discussion 803).Google Scholar
  47. 47.
    Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009;182(5):2242–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868–76.CrossRefPubMedGoogle Scholar
  49. 49.
    Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53(5):941–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Spina CS. Androgen deprivation therapy and radiation therapy for prostate cancer: the mechanism underlying therapeutic synergy. Transl Cancer Res. 2018;7(Suppl. 6):S695–S703.Google Scholar
  51. 51.
    Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866–73.CrossRefPubMedGoogle Scholar
  52. 52.
    D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95.CrossRefPubMedGoogle Scholar
  53. 53.
    D’Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3.Google Scholar
  54. 54.
    Giacalone NJ, Wu J, Chen MH, Renshaw A, Loffredo M, Kantoff PW, et al. Prostate-specific antigen failure and risk of death within comorbidity subgroups among men with unfavorable-risk prostate cancer treated in a randomized trial. J Clin Oncol. 2016;34(31):3781–6.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97(2):247–54.CrossRefPubMedGoogle Scholar
  56. 56.
    Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105(8):1074–81.Google Scholar
  57. 57.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.Google Scholar
  58. 58.
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172(5 Pt 2):S42-6 (discussion S6–7).Google Scholar
  59. 59.
    Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23(4):826–31.CrossRefPubMedGoogle Scholar
  60. 60.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64(6):1182–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Spry NA, Galvao DA, Davies R, La Bianca S, Joseph D, Davidson A, et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 2009;104(6):806–12.CrossRefPubMedGoogle Scholar
  64. 64.
    Efstathiou E, Wang X, Zurita AJ, Tu S-M, Aparicio A, Wang J, et al. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC). J Clin Oncol. 2018;36(15_suppl):5002.Google Scholar
  65. 65.
    (CHMP) EMAECfMPfHU. EMA/CHMP/784876/2018 15 November 2018.Google Scholar
  66. 66.
    (FDA) FaDA. ERLEADA (apalutamide) tablets, for oral use 2018.Google Scholar
  67. 67.
    (FDA) FaDA. XTANDI® (enzalutamide) capsules, for oral use 2018.Google Scholar
  68. 68.
    EMA. Xtandi: EPAR—Product information. In: European Medicines Agency. 2018. https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf. Accessed 3 Feb 2019.
  69. 69.
    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.CrossRefPubMedGoogle Scholar
  70. 70.
    Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(10):1404–16.CrossRefPubMedGoogle Scholar
  71. 71.
    Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clini Oncol. 2019;37(7_suppl):144.Google Scholar
  72. 72.
    Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.CrossRefPubMedGoogle Scholar
  73. 73.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–46.CrossRefPubMedGoogle Scholar
  74. 74.
    Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–25.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Mottet N, De Santis M, Briers E, Bourke L, Gillessen S, Grummet JP, et al. Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard. Eur Urol. 2017.  https://doi.org/10.1016/j.eururo.2017.09.029.CrossRefPubMedGoogle Scholar
  76. 76.
    Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R, et al. (2018). Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2),178–211.Google Scholar
  77. 77.
    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.CrossRefPubMedGoogle Scholar
  78. 78.
    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Fizazi K, Tran N, Fein LE, Matsubara N, Antolín AR, Ozguroglu M, et al. Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA + P) added to androgen deprivation therapy (ADT). J Clin Oncol. 2019;37(7_suppl):141.Google Scholar
  80. 80.
    Chi KN, Protheroe A, Rodriguez-Antolin A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194–206.CrossRefPubMedGoogle Scholar
  81. 81.
    Hoyle AP, Ali SA, James ND, Parker CC, Cook AD, Attard G, et al. LBA4 effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Ann Oncol. 2018;29(suppl_8):mdy424.033-mdy424.033.Google Scholar
  82. 82.
    Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–48.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2018;73(6):834–44.CrossRefPubMedGoogle Scholar
  87. 87.
    Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410–8.CrossRefPubMedGoogle Scholar
  89. 89.
    Chang S, Goldstein NE, Dharmarajan KV. Managing an older adult with cancer: considerations for radiation oncologists. Biomed Res Int. 2017;2017:1695101.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, et al. Age-associated hematological toxicity in patients with metastatic castration-resistant prostate cancer treated with docetaxel in clinical practice. Drugs Aging. 2019;36(4):379–85.CrossRefPubMedGoogle Scholar
  91. 91.
    Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(48):84572–8.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.CrossRefPubMedGoogle Scholar
  94. 94.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.CrossRefPubMedGoogle Scholar
  95. 95.
    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRefPubMedGoogle Scholar
  96. 96.
    Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.CrossRefPubMedGoogle Scholar
  97. 97.
    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7.CrossRefPubMedGoogle Scholar
  99. 99.
    Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. Eur Urol. 2018.  https://doi.org/10.1016/j.eururo.2018.12.015.CrossRefPubMedGoogle Scholar
  100. 100.
    Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, et al. Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;72(1):10–3.CrossRefPubMedGoogle Scholar
  101. 101.
    Scher H, Morris M, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96(3):498–506.CrossRefPubMedGoogle Scholar
  103. 103.
    Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009;55(1):62–75.CrossRefPubMedGoogle Scholar
  104. 104.
    Kintzel PE, Chase SL, Schultz LM, O’Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28(12):1511–22.CrossRefPubMedGoogle Scholar
  105. 105.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.CrossRefPubMedGoogle Scholar
  106. 106.
    Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93(6):2042–9.CrossRefPubMedGoogle Scholar
  107. 107.
    Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(Suppl 5):3–13.CrossRefPubMedGoogle Scholar
  108. 108.
    Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006;4(9):687–96.PubMedGoogle Scholar
  109. 109.
    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.CrossRefPubMedGoogle Scholar
  110. 110.
    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.CrossRefPubMedGoogle Scholar
  111. 111.
    Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86(6):2787–91.PubMedGoogle Scholar
  112. 112.
    Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMedGoogle Scholar
  114. 114.
    Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9.CrossRefPubMedGoogle Scholar
  115. 115.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.CrossRefPubMedGoogle Scholar
  116. 116.
    Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175(1):136–9 (discussion 9).Google Scholar
  117. 117.
    Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ. Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med. 2004;26(5):436–42.CrossRefPubMedGoogle Scholar
  118. 118.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64(2):335–40.CrossRefPubMedGoogle Scholar
  119. 119.
    Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–7.CrossRefPubMedGoogle Scholar
  120. 120.
    Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V, et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer. 2005;103(10):2042–52.CrossRefPubMedGoogle Scholar
  121. 121.
    D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420–5.CrossRefPubMedGoogle Scholar
  122. 122.
    Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24.CrossRefPubMedGoogle Scholar
  123. 123.
    Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118(13):3397–406.CrossRefPubMedGoogle Scholar
  124. 124.
    Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012;82(4):1411–6.CrossRefPubMedGoogle Scholar
  125. 125.
    Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer. 2013;11(4):375–84.CrossRefPubMedGoogle Scholar
  126. 126.
    Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93(7):975–9.CrossRefPubMedGoogle Scholar
  127. 127.
    Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90(4):427–32.CrossRefPubMedGoogle Scholar
  128. 128.
    Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 2005;96(1):48–53.CrossRefPubMedGoogle Scholar
  129. 129.
    Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003;170(5):1808–11.CrossRefPubMedGoogle Scholar
  130. 130.
    Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199(6):1417–25.CrossRefPubMedGoogle Scholar
  131. 131.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465–71.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Llorente MD, Burke M, Gregory GR, Bosworth HB, Grambow SC, Horner RD, et al. Prostate cancer: a significant risk factor for late-life suicide. Am J Geriatr Psychiatry. 2005;13(3):195–201.CrossRefPubMedGoogle Scholar
  133. 133.
    Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014;65(5):875–83.CrossRefPubMedGoogle Scholar
  134. 134.
    Parimi S, Eigl BJ, Sunderland K, Zulfiqar M, Finch DL, Oja CD, et al. Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2016;34(15_suppl):5059.Google Scholar
  135. 135.
    Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. ESMO Open. 2018;3(5):e000397.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017;55:71–82.CrossRefPubMedGoogle Scholar
  137. 137.
    Fizazi K, Smith MR, Tombal B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Myrto Boukovala
    • 1
  • Nicholas Spetsieris
    • 1
  • Eleni Efstathiou
    • 1
    Email author
  1. 1.Department of Genitourinary Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations